Aspirin use after a prostate cancer diagnosis and cancer survival in a prospective cohort

Cancer Prevention Research

Volumn 5, Issue 10, 2012, Pages 1223-1228

  Dhillon, Preet K ^a,b,d   Kenfield, Stacey A ^a,b   Stampfer, Meir J ^a,b   Giovannucci, Edward L ^a,b   Chan, June M ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d PUBLIC HEALTH FOUNDATION OF INDIA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID;

AGED; ARTICLE; BRACHYTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; DRUG USE; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RISK FACTOR; WATCHFUL WAITING;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CALIFORNIA; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84867372961     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0171     Document Type: Article

References (23)

1. Sooriakumaran P, Coley HM, Fox SB, Macanas-Pirard P, Lovell DP, Henderson A, et al. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res 2009;29:1483-8.
2. Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM, et al. Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specifi c biomarkers. J Clin Oncol 2009;27:4986-93.
3. Smith MR, Manola J, Kaufman DS, Oh WK, Bubley GJ, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-speci fi c antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol. 2006;24:2723-8. (Pubitemid 46630568)
4. Pruthi RS, Derksen JE, Moore D, Carson CC, Grigson G, Watkins C, et al. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. Clin Cancer Res. 2006;12:2172-7.
5. Ganswindt U, Budach W, Jendrossek V, Becker G, Bamberg M, Belka C. Combination of celecoxib with percutaneous radiotherapy in patients with localised prostate cancer - a phase I study. Radiat Oncol 2006;1:9.
6. Sooriakumaran P, Macanas-Pirard P, Bucca G, Henderson A, Langley SE, Laing RW, et al. A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer. Cancer Genomics Proteomics 2009;6:93-9.
7. Cai Y, Lee YF, Li G, Liu S, Bao BY, Huang J, et al.Anew prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. Int J Cancer 2008;123:195-201. (Pubitemid 351705209)
8. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, et al. Aspirin and non-steroidal anti-infl ammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009;10:501-7.
9. Rothwell PM, Wilson M, Price JF, Belch JFF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379:1591-601.
10. Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL. Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer 2011;128:2444-52.
11. Mahmud S, Franco E, Aprikian A. Prostate cancer and use of nonsteroidal anti-inflammatory drugs: systematic review and meta-analysis. Br J Cancer 2004;90:93-9. (Pubitemid 38174945)
12. Gonzalez-Perez A, Garcia Rodriguez LA, Lopez-Ridaura R. Effects of non-steroidal anti-inflammatory drugs on cancer sites other than the colon and rectum: a meta-analysis. BMC Cancer 2003;3:28.
13. Rimm EB, Giovannucci EL, Stampfer MJ, Colditz GA, Litin LB, Willett WC. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. Am J Epidemiol 1992;135:1114-26; discussion 1127-36.
14. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate Suppl 1992;4:129-38.
15. Stampfer MJ, Willett WC, Speizer FE, Dysert DC, Lipnick R, Rosner B, et al. Test of the National Death Index. Am J Epidemiol 1984;119:837-9. (Pubitemid 14142821)
16. Giovannucci E, Liu Y, Platz EA, Stampfer MJ, Willett WC. Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. Int J Cancer 2007;121:1571-8. (Pubitemid 47328718)
17. Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, et al. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence. J Natl Cancer Inst 2005;97:975-80. (Pubitemid 41430563)
18. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-15. (Pubitemid 47073542)
19. Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, et al. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res 2008;68:6762-9.
20. Lu W, Tinsley HN, Keeton A, Qu Z, Piazza GA, Li Y. Suppression of Wnt/beta-catenin signaling inhibits prostate cancer cell proliferation. Eur J Pharmacol 2009;602:8-14.
21. D'Amico AV, Kantoff PW, Chen MH. Aspirin and hormone therapy for prostate cancer. N Engl J Med 2007;357:2737-8.
22. Murray NP, Calaf GM, Badinez L. Presence of prostate cells in bone marrow biopsies as a sign of micrometastasis in cancer patients. Oncol Rep 2009;21:571-5.
23. Wood DP Jr, Banks ER, Humphreys S, McRoberts JW, Rangnekar VM. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 1994;74:2533-40. (Pubitemid 24320859)